抗合成酶综合征:远不止肌病
该综述系统总结了抗合成酶综合征(ASS)的流行病学、发病机制、现有诊断标准、临床表现异质性、预后因素及治疗选择。ASS虽归类为特发性炎性肌病亚型,但肌炎未必是突出表现,临床表现高度异质,现有分类标准与临床模式不完全对应,治疗以糖皮质激素和其他免疫抑制剂为基础,亟需针对ASS的随机对照试验。
要点
- ASS临床表现高度异质,肌炎未必是突出表现,应视为异质性谱系而非均一疾病实体。
- 现有分类标准与ASS实际临床模式不完全对应,诊断需综合抗体与多系统表现。
- 治疗以糖皮质激素和其他免疫抑制剂为基础,尚缺乏针对ASS的随机对照试验证据。
核心结论
- ASS应被视为异质性谱系而非均一疾病实体,肌炎未必是突出表现。
- 现有分类标准与疾病临床模式不完全对应,亟需针对ASS的随机对照试验以形成治疗算法。
研究设计与样本
- 综述类:于2020年2月至4月检索PubMed数据库,检索词为「antisynthetase syndrome」或「antisynthetase antibodies」。
主要发现
- 氨酰-tRNA合成酶作为抗原参与免疫系统激活,并发挥趋化及类细胞因子作用,启动固有与适应性免疫通路。
- 吸入多种抗原暴露可能诱导自身免疫级联反应导致ASS。
- NK细胞干扰素-γ产生受损及中性粒细胞NETs形成参与发病。
- 症状患病率因研究而异,肌肉、关节和肺部受累最常见。
- ASS虽归类为特发性炎性肌病亚型,但肌炎未必是突出表现。
关键数值与推荐
- 现有分类标准与ASS临床模式不完全对应。
- 治疗以糖皮质激素和其他免疫抑制剂为基础。
临床怎么用
- 临床应认识到ASS为多系统异质性谱系,不应仅以肌炎有无判断。
- 诊断需结合抗合成酶抗体与肌肉、关节、肺部等多系统表现综合评估。
- 治疗以糖皮质激素和其他免疫抑制剂为基础,目前尚无针对ASS的随机对照试验指导算法。
局限性
- 为叙述性综述,检索限于PubMed且时间范围为2020年2月至4月。
- 症状患病率因研究而异,缺乏统一数据。
- 现有分类标准与临床模式不完全对应。
- 缺乏针对ASS患者的随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of the study was to summarize current knowledge on antisynthetase syndrome (ASS), including its epidemiology, pathogenesis, proposed so far diagnostic criteria, heterogeneity of clinical manifestations, prognostic factors and therapeutic possibilities. PubMed database was screened for "antisynthetase syndrome" OR "antisynthetase antibodies" between February and April 2020. Aminoacyl-tRNA synthetases participate in the immune system activation as antigens, but also serve chemoattractive and cytokine-resembling roles, initiating innate and adaptive pathways. Exposure to various inhaled antigens may induce the autoimmune cascade leading to ASS. NK cells with its impaired INF-y production as well as formation of NETs by neutrophils contribute to pathogenesis. The prevalence of symptoms vary significantly depending on the study with muscular, articular and pulmonary involvement being the most frequently observed. Although classified as subtype of idiopathic inflammatory myopathies, myositis may not necessarily be the prominent manifestation. Since clinical presentation is heterogeneous and symptoms can emerge gradually, ASS could be considered as a heterogeneous spectrum rather than a homogenous disease entity. The currently available classification criteria do not fully correspond with the clinical patterns of the disease. Therapy is based on glucocorticosteroids and other immunosuppressive agents. Randomized controlled trials, dedicated for patients with ASS, are needed to form treatment algorithms.
引用
- Opinc AH, Makowska JS. Antisynthetase syndrome - much more than just a myopathy. Semin Arthritis Rheum. 2020. PMID: 33360231. doi:10.1016/j.semarthrit.2020.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。